BHRT for Women: Menopause & Perimenopause Hormone Therapy

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·12 min read

Bioidentical hormone replacement therapy (BHRT) for women addresses one of the most common, and most undertreated, transitions in medicine: the decline of ovarian hormones through perimenopause and menopause. For a large share of women, that decline is not a quiet background event — it arrives as hot flashes, broken sleep, mood instability, vaginal and urinary change, and a loss of energy and libido that reshapes daily life. BHRT replaces what the ovaries no longer reliably make, using hormones that are structurally identical to the body’s own.

This guide is written for clinicians and situates women’s hormone therapy within the broader field of bioidentical hormone replacement therapy. It is clinical education, not medical advice, and deliberately stops short of specific patient dosing and titration — those decisions belong to current standards of care and individualized judgment.

The hormonal changes of perimenopause and menopause

Two ovarian hormones do most of the work across a woman’s reproductive life. Estrogen — predominantly estradiol, the most potent of the three estrogens — is produced mainly in the ovaries and acts on tissue throughout the body, including the uterus, breast, brain, liver, and bone. Progesterone is produced in the second half of the cycle by the corpus luteum that forms after ovulation; it prepares the uterus for implantation and, as Dr. Greenleaf frames it, is “responsible for feelings of emotional well-being.” As cycles wind down, both fall — and they rarely fall in step.

Perimenopause is the turbulent prelude. It can begin in the mid-thirties and presents with the hallmark signs of hormonal imbalance: irregular periods, heavy or light bleeding, moodiness, night sweats, hot flashes, weight changes, and shifts in libido. A recurring pattern is relatively high estrogen against low progesterone, which can drive abnormal bleeding and is one reason perimenopausal women may also become iron-depleted. Two clinical points matter here. First, pregnancy is still possible — birth control remains a real consideration, and oral contraceptive hormones are not bioequivalent to bioidentical therapy. Second, perimenopausal women are harder to test, because cycle irregularity makes timing a moving target.

Menopause is, by definition, retrospective: twelve consecutive months without a period. If a woman goes ten months without bleeding and then bleeds again, the clock restarts. Natural menopause can begin as early as thirty-eight, with the average around fifty to fifty-two. An important point for testing: menopausal patients can be tested at any time, and a single elevated FSH does not diagnose menopause — only a full year without a period does. After menopause, the ovaries largely stop producing estrogen and progesterone, and most circulating testosterone is made in the adrenal glands.

Symptoms of estrogen and progesterone decline

The symptom picture of declining ovarian hormones is broad because the receptors are everywhere. Falling estrogen in women classically presents as irregular or absent periods, hot flashes, night sweats, sleeping difficulties, mood swings, changes in libido, and dryness of the skin and tissues. Low progesterone overlaps and adds its own signature: irregular or absent periods, heavy and painful periods, mood swings, weight gain, decreased sex drive, and hot flashes.

• Vasomotor: hot flashes and night sweats — the symptoms patients most readily name and often the first to respond to therapy.
• Sleep: difficulty sleeping, frequently compounded by night sweats, which then feeds daytime fatigue and mood.
• Mood: mood swings and irritability; the progesterone connection to emotional well-being makes this more than incidental.
• Genitourinary: vaginal and tissue dryness driven by estrogen withdrawal — a domain a urogynecologist treats directly, and one patients underreport.
• Libido: declining sex drive, which is multifactorial and not solved by testosterone alone (more below).
• Cognition and energy: low energy and the “brain fog” many women describe, consistent with estrogen’s activity in the brain.

Dr. Greenleaf often anchors the picture with a representative patient — a menopausal woman with low sex drive, vaginal dryness, hot flashes, low energy, and hair loss. That cluster, not any single complaint, is what brings women in. Validated symptom questionnaires are a useful way to track progress over time, and they become especially important if a practice is billing insurance.

The hormones women need: estrogen, progesterone, and testosterone

Most women on BHRT need some combination of three hormones, balanced against one another rather than dosed in isolation.

Estrogen

Estrogen replacement most often means estradiol, the most bioactive of the three natural estrogens and the one most commonly used in therapy. Estrone is weaker and produced largely in adipose tissue; estriol is the weakest but appears to have some protective effect on breast tissue. The bioidentical distinction is central: naturally occurring estradiol behaves very differently in the body from synthetic or horse-derived estrogens, which bind estrogen receptors more avidly, can make levels look artificially high, and are more often metabolized down inflammatory or genotoxic pathways. See our dedicated guide on estrogen replacement therapy.

Progesterone

Progesterone is not optional for women with a uterus. Any woman with a uterus who receives estrogen must also receive progesterone — unopposed estrogen increases endometrial cancer risk. Bioidentical micronized progesterone (the molecule in Prometrium) is the preferred form; it does not carry the weight gain, anxiety, and depression associated with synthetic progestins like the medroxyprogesterone implicated in the WHI. Because hormones interconvert, women receiving testosterone or DHEA also need uterine protection. Our companion guide covers progesterone therapy in depth.

Low-dose testosterone

Testosterone is not just a male hormone. It declines in women as the ovaries fail, and its receptors live in muscle, bone, skin, hair follicles, brain, and reproductive tissue. Low testosterone in women can present as fatigue, decreased sex drive, mood changes, decreased muscle mass, increased body fat, and menstrual irregularities. A clinical caution Dr. Greenleaf emphasizes: testosterone is often treated as the single answer to low libido, but libido is far more complex, and women seeking treatment for low sex drive frequently do not get the improvement they expect from raising testosterone alone. Used judiciously and at female-appropriate low doses, it remains a valuable part of the picture. See our guide on testosterone replacement therapy.

Delivery options, including pellets

Bioidentical hormones can be delivered orally, transdermally, vaginally, by injection, or by subcutaneous pellet. Pellets are small, tablet-like compounds placed under the skin for slow release over roughly three to six months. Their appeal is a steady release that avoids the peaks and troughs of some other methods, high bioavailability, no first-pass liver strain, and good patient satisfaction for ease of use.

The trade-offs are real and worth stating plainly. Pellet insertion is a minor surgical procedure that carries procedural risk; once placed, a pellet cannot easily be removed or its dose adjusted; absorption can vary from person to person and batch to batch; and there is a higher risk of overcorrection. A subtler point: because the body tends to “tune out” hormones held at a flat steady state — it is natural fluctuation that keeps receptors sensitive — some patients report that pellets “stopped working,” a hormonal insensitivity that can be managed by spacing placement further apart or bridging with short-acting transdermals. For the full clinical and procedural picture, see hormone pellet therapy.

Benefits of well-balanced BHRT

The goal of BHRT in women is not a lab number — it is symptom relief and quality of life. When therapy is balanced and well-monitored, women commonly report improvement in the vasomotor symptoms that disrupt their days and nights, better sleep, steadier mood, relief of genitourinary dryness, and a return of energy and libido. Estrogen’s activity in bone is relevant to long-term skeletal health, and in the WHI estrogen-only data, hormone exposure was associated with a decreased risk of osteoporosis, colon cancer, and — notably — breast cancer.

The honest framing is that benefit is individualized and tied to the right candidate, the right hormones, and the right balance. BHRT is a tool for restoring function in symptomatic women, not a universal “fountain of youth.” That overreach is exactly the framing that, historically, set the field up for the backlash that followed.

Safety and what the WHI actually showed

No honest discussion of women’s hormone therapy can skip the Women’s Health Initiative. Before 2000, hormones were marketed as a fountain of youth; the WHI upended that. The study was designed to examine major causes of death, disability, and quality of life in postmenopausal women — cardiovascular disease, cancer, and osteoporosis — and it was stopped early over a presumed rise in heart disease and cancer.

Two facts are essential to read the result honestly. First, the population studied was older, with a baseline risk profile that may not reflect a symptomatic woman starting therapy near menopause. Second, and more important, the study used non-bioidentical hormones — conjugated equine estrogen and medroxyprogesterone acetate. It was the combined arm that showed higher risk of heart disease, stroke, blood clots, and breast cancer. The estrogen-only arm told a different story: increased risk of stroke and blood clots, but a decreased risk of breast cancer, colon cancer, and osteoporosis. The media compressed all of this into “hormones cause cancer,” and that fear persists today.

The clinically accurate statement is this: hormones do not typically cause cancer, but hormone-dependent tumors with hormone receptors can have their growth stimulated by hormone therapy. That is why health screening and ongoing follow-up are non-negotiable, why uterine protection with progesterone is mandatory in women with a uterus, and why bioidentical preparations — which carry a lower risk profile than the synthetic hormones the WHI tested — are the foundation of modern BHRT. The evidence base for bioidentical products is itself limited, because non-patentable compounds attract little research funding; that limitation argues for conservative dosing and close monitoring, not for ignoring the data.

Candidacy, evaluation, and monitoring

The ideal candidates for hormone therapy are menopausal women with symptoms. Perimenopausal women will often see symptom improvement too, but their contraceptive needs must be addressed first. Women with conditions that cause hormonal imbalance — premature menopause, hypogonadism — are also candidates. Pellets specifically are intended for women in menopause, not for those of childbearing age who wish to preserve fertility; short-acting options or avoidance are more appropriate there.

Contraindications are firm. Hormone-sensitive cancers (breast, uterine, ovarian), a history of blood clots, stroke, or heart disease, liver disease, pregnancy or breastfeeding, unexplained vaginal bleeding, and allergy to the preparation all take a patient out of consideration. Estrogen in particular is contraindicated with breast, uterine, or ovarian cancer and a history of thrombotic disease.

Evaluation begins like any new-patient workup: a detailed history and physical, including prior therapies, supplements, and over-the-counters patients often forget. Ask about stress and toxin exposure — hormone balance and chronic stress cannot coexist, and endocrine disruptors can confound otherwise puzzling labs. A reasonable laboratory panel includes a CBC, CMP, cholesterol and triglycerides, inflammatory markers, and hormone levels. Timing of testing matters: cycling women test by symptom-directed timing (estradiol peaks around day three, progesterone around day twenty-one), menopausal women can be tested anytime, and perimenopausal women require clinical judgment. The guiding philosophy throughout is start low, go slow, and treat the patient’s symptoms against her labs — not the labs alone. The specific dosing ranges, titration logic, and conversion math are exactly what Empire’s training is built to teach.

Training for providers

Prescribing BHRT for women competently means holding several threads at once: female hormone physiology, the perimenopause-to-menopause arc, the estrogen-progesterone-testosterone balance, mandatory uterine protection, an evidence-honest reading of the WHI, contraindications, symptom-directed lab interpretation, and the practical realities of each delivery route. Structured, physician-taught education is how providers move from understanding the science to using it safely in real patients.

Empire’s curriculum is built around exactly this judgment, taught by a board-certified OB/GYN and urogynecologist, and connects the science of bioidentical therapy to hands-on hormone pellet training for clinicians building or expanding a hormone practice responsibly.